Madison, United States
Stemina Biomarker Discovery, Inc., founded in 2007, is at the forefront of leveraging metabolomics to enhance drug safety and public health. The company has positioned itself as a pioneer through its slogan, “Pioneer of human in vitro systems for toxicology and compound safety screening to improve human health.” Its unique approach combines human embryonic stem (hES) cells with advanced metabolomics, using mass spectrometry to measure small molecule responses to drugs, injury, or disease.
Operating from Madison, Wisconsin, Stemina caters predominantly to the Biotechnology, Health Care, and Pharmaceutical industries. The company last secured a $3.10M Venture Round investment on January 1, 2017, with prominent investors such as Wisconsin Investment Partners, BrightStar Wisconsin Foundation, and NeuroNetworks Fund backing their initiatives. Stemina’s cutting-edge research facility supports its mission to drive innovation in biomarker discovery.
